All In MedTech

Device Trial Radar · NCT07836855

A Fellow Eye Comparative Study of the Aquea Intracanalicular Glaucoma Micro-coil Stent and the Alcon Hydrus Glaucoma Microstent

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Sep 16, 2024

Primary completion

Jun 15, 2026

Study completion Jun 15, 2026

Sponsor

Lead sponsor
Aquea Health, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Sep 23, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research study is to compare the safety and effectiveness of the Aquea Intracanalicular Glaucoma Stent to the Alcon Hydrus Glaucoma Microstent for the reduction of intraocular pressure (IOP) in patients with cataract and primary open angle glaucoma.

Conditions

  • Cataract Senile
  • Glaucoma, Open Angle

Interventions

  • Aquea Zealix™Device

    The Zealix stent is a helical shaped stent with variable pitch across the length of the implant specifically designed to keep Schlemm's canal adequately dilated to its natural healthy diameter. The stent has been designed to reduce IOP by restoring the conventional outflow pathway for aqueous humor, specifically Schlemm's canal (SC). Additionally, the Apquea Zealix stent is also designed to provide a by-pass for the aqueous humor fluid to enter Schlemm's canal and flow unobstructed to access the collector channels for drainage.

  • Hydrus® MicrostentDevice

    The Hydrus® Microstent is an FDA approved device. It is a crescent-shaped implantable microstent pre-loaded onto a hand-held delivery system. It is composed of nitinol, a metal alloy of nickel (Ni) and titanium (Ti). The microstent is approximately 8mm in overall length with major and minor axes of 292μm and 185μm, respectively. The length and curvature of the implant are designed to occupy approximately 90° or 3 clock hours of Schlemm's canal. The implant is designed to have adequate structural thickness to support the tissue of the canal while providing maximum open flow areas through the canal, with the proximal portion of the implant exiting the canal through the trabecular meshwork to allow inflow of aqueous humor from the anterior chamber. A further description of the device and delivery system, and a summary of pre-clinical and clinical testing, can be found in Instructions for Use (IFU) provided by the manufacturer with the device

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness EndpointTime frame: 12 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centro Oftalmologico Robles

    Santa Rosa de Copán, Honduras

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.